Advertisement

Cancer Cachexia and Fat Metabolism

  • Josep M. Argilés
  • Vanessa Almendro
  • Sílvia Busquets
  • Francisco J. López-Soriano

Abstract

Cancer cachexia is one of the worst effects of malignancy, accounting for nearly a third of cancer deaths. It is a pathological state characterised by weight loss together with anorexia, weakness, anaemia, and asthaenia. The complications associated with the appearance of the cachectic syndrome affect both the physiological and biochemical balance of the patient and influence the efficiency of anticancer treatment, resulting in a considerably decreased survival time. At the metabolic level, cachexia is associated with loss of body lipid stores. Alterations in lipid metabolism are partially mediated by changes in circulating hormone concentrations (insulin, glucagon, and glucocorticoids, in particular) or in their effectiveness. However, a large number of observations point towards cytokines, polypeptides released mainly by immune cells, as the molecules responsible for the above-mentioned metabolic derangements. The role of humoral factors in fat metabolism in the cancer patient has been discussed; among cytokines, tumour necrosis factor-α (TNF-α) seems to have a key role in the lipid metabolic changes associated with cancer cachexia.

Keywords

Adipose Tissue White Adipose Tissue Bulimia Nervosa Cancer Cachexia Lipoprotein Lipase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thompson MP, Koons JE, Tan ETH, Grigor MR (1981) Modified lipoprotein lipase activities, rates of lipogenesis, and lipolysis as factors leading to lipid depletion in C57BL mice bearing the preputial gland tumor, ESR-586. Cancer Res 41:3228–3232PubMedGoogle Scholar
  2. 2.
    Shaw JHF, Wolfe RR (1987)) Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 205:368–376PubMedCrossRefGoogle Scholar
  3. 3.
    Imagawa W, Bandyopadhyay G, Wallace D, Nadi S (1989) Phospholipids containing polyunsaturated acyl groups are mitogenic for normal mouse mammary epithelial cells in serum free primary cell culture. Proc Natl Acad Sci USA 86:4122–4126PubMedCrossRefGoogle Scholar
  4. 4.
    Lanza-Jacoby S, Lansey SC, Miller EE, Cleary MP (1984) Sequential changes in the activities of lipoprotein lipase and lipogenic enzymes during tumor growth in rats. Cancer Res 44:5062–5067PubMedGoogle Scholar
  5. 5.
    Noguchi Y, Vydelingum NA, Younes RN et al (1991) Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels. Cancer Res 51:863–869PubMedGoogle Scholar
  6. 6.
    Muscaritoli M, Cangiano C, Cascino A et al (1990) Plasma clearance of exogenous lipids in patients with malignant disease. Nutrition 6:147–151PubMedGoogle Scholar
  7. 7.
    López-Soriano J, Argilés JM, López-Soriano FJ (1996) Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Mol Cell Biochem 165:17–23PubMedCrossRefGoogle Scholar
  8. 8.
    Evans RD, Williamson DH (1988) Tissue-specific effects of rapid tumour growth on lipid metabolism in the rat during lactation and on litter removal. Biochem J 252:65–72PubMedGoogle Scholar
  9. 9.
    Mulligan HD, Tisdale MJ (1991) Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. Br J Cancer 63:719–722PubMedGoogle Scholar
  10. 10.
    Dessi S, Batetta B, Pulisci D et al (1991) Total and HDL cholesterol in human and hematologie neoplasms. Int J Hematol 54:483–486PubMedGoogle Scholar
  11. 11.
    Dessi S, Batetta B, Anchisi C et al (1992) Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). BrJ Cancer 66:787–793Google Scholar
  12. 12.
    Dessi S, Batetta B, Spano O et al (1995) Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor-a treatment in rats bearing an ascites hepatoma (Yoshida AH-130). BrJ Cancer 72:1138–1143Google Scholar
  13. 13.
    Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res 25:1017–1058PubMedGoogle Scholar
  14. 14.
    Fanelli FR, Cangiano C, Muscaritoli M et al (1995) Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition 11:595–600Google Scholar
  15. 15.
    Price SR, Olivecrona T, Pekala PH (1986) Regulation of lipoprotein lipase synthesis by recombinant tumour necrosis factor: the primary regulatory role of the hormone in 3T3-L1 adipocytes. Arch Biochem Biophys 251:738–746PubMedCrossRefGoogle Scholar
  16. 16.
    Cornelius P, Enerback S, Bjursell G et al (1988) Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. Biochem J 249:765–769PubMedGoogle Scholar
  17. 17.
    Fried SK, Zechner R (1989) Cachectin/tumour necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res 30:1917–1923PubMedGoogle Scholar
  18. 18.
    Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumour necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262:8390–8394PubMedGoogle Scholar
  19. 19.
    Evans RD, Williamson DH (1988) Tumour necrosis factor-a (cachectin) mimics some of the effects of tumour growth on the disposal of α [14C]lipid load in virgin, lactating and litter-removed rats. Biochem J 256:1055–1058PubMedGoogle Scholar
  20. 20.
    Feingold KR, Grunfeld C (1987) Tumour necrosis factor-a stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 80:1384–1389Google Scholar
  21. 21.
    Krauss RM, Grunfeld C, Doerrler WT, Feingold KR (1990) Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition. Endocrinology 127:1016–1021PubMedGoogle Scholar
  22. 22.
    Kern PA (1988) Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. J Lipid Res 29:909–914PubMedGoogle Scholar
  23. 23.
    Kawakami M, Murase T, Ogawa H et al (1987) Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J Biochem 101:331–338PubMedGoogle Scholar
  24. 24.
    Feingold KR, Doerrler W, Dinarello CA et al (1992) Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and interferons is blocked by inhibition of prostaglandins synthesis. Endocrinology 130:10–16PubMedCrossRefGoogle Scholar
  25. 25.
    Hauner H, Petruschke T, Russ M et al (1995) Effects of tumor necrosis factor-alpha (TNF-a) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38:764–771PubMedCrossRefGoogle Scholar
  26. 26.
    Pape ME, Kim KH (1988) Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and pre-adipocyte differentiation. Mol Endocrinol 2:395–403PubMedCrossRefGoogle Scholar
  27. 27.
    Carbö N, Costelli P, Tessitore L et al (1994) Antitumor necrosis factor-a treatment interferes with changes in lipid metabolism in a cachectic tumor model. Clin Sci 87:349–355PubMedGoogle Scholar
  28. 28.
    Patton JS, Shepard HM, Wilking H et al (1986) Interferons and tumor necrosis factors have similar catabolic effects on 3T3 LI cells. Proc Natl Acad Sci USA 83:8313–8317PubMedCrossRefGoogle Scholar
  29. 29.
    Tisdale MJ (1999) Wasting in cancer. J Nutr 129(1S Suppl):243S–246SPubMedGoogle Scholar
  30. 30.
    Gregoire F, De Broux N, Hauser N et al (1992) Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes. J Cell Physiol 151:300–309PubMedCrossRefGoogle Scholar
  31. 31.
    Grunfeld C, Adi S, Soued M et al (1990) Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. Cancer Res 50:4233–4238PubMedGoogle Scholar
  32. 32.
    Grunfeld C, Soued M, Adi S et al (1990) Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. Endocrinology 127:46–54PubMedCrossRefGoogle Scholar
  33. 33.
    Grunfeld C, Soued M, Adi S et al (1991) Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-alpha. Cancer Res 51:2803–2807PubMedGoogle Scholar
  34. 34.
    Zhang Y, Proenca R, Maffei M et al (1994) Positional cloning of the mouse obese gene and its human analogue. Nature 372:425–432PubMedCrossRefGoogle Scholar
  35. 35.
    Phillips MS, Liu Q, Hammond HA et al (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18–19PubMedCrossRefGoogle Scholar
  36. 36.
    Madej T, Boguski MS, Bryant SH (1995) Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 373:13–18PubMedCrossRefGoogle Scholar
  37. 37.
    Hamann A, Matthaei S (1996) Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 104:293–300PubMedCrossRefGoogle Scholar
  38. 38.
    Grunfeld C, Zhao C, Fuller Jet al (1996) Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 97:2152–2157PubMedGoogle Scholar
  39. 39.
    Tanaka J, Nomura M (1993) Involvement of neurons sensitive to angiotensin II in the median preoptic nucleus in the drinking response induced by angiotensin II activation of the subfornical organ in rats. Exp Neurol 119:235–239PubMedCrossRefGoogle Scholar
  40. 40.
    Rothwell NJ (1993) Cytokines and thermogenesis. IntJ Obesity 17:S98–S101Google Scholar
  41. 41.
    Remesar X, Rafecas I, Fernandez-López JA, Alemany M (1997) Is leptin an insulin counter-regulatory hormone? FEBS Lett 402:9–11PubMedCrossRefGoogle Scholar
  42. 42.
    Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69:381–387PubMedGoogle Scholar
  43. 43.
    Astrup T (1978) Fibrinolysis: an overview. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC (eds) Progress in chemical fibrinolysis and thrombolysis. Raven Press, New York, pp 1–57Google Scholar
  44. 44.
    Vassalli JD, Sappini AP, Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88:1067–1072PubMedGoogle Scholar
  45. 45.
    McGill JB, Schneider DJ, Arfken CL et al (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104–109PubMedCrossRefGoogle Scholar
  46. 46.
    Vague P, Juhan-Vague I, Chabert V et al (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metab Clin Exp 38:913–915PubMedGoogle Scholar
  47. 47.
    Samad F, Yamamoto K, Loskutoff DJ (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-a and lipopolysaccharide. J Clin Invest 97:37–46PubMedCrossRefGoogle Scholar
  48. 48.
    Flier JS, Cook KS, Usher P, Spiegelman BM (1987) Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405–408PubMedCrossRefGoogle Scholar
  49. 49.
    Napolitano A, Lowell BB, Damm D et al (1994) Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obesity 18:213–218Google Scholar
  50. 50.
    Cianflone K, Roncari DA, Maslowska M et al (1994) Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 33:9489–9495PubMedCrossRefGoogle Scholar
  51. 51.
    Tao Y, Cianflone K, Sniderman AD et al (1997) Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta 1344:221–229PubMedGoogle Scholar
  52. 52.
    Maslowska M, Sniderman AD, Germinario R, Cianflone K (1997) ASP stimulates glucose transport in cultured human adipocytes. Int J Obesity 21:261–266CrossRefGoogle Scholar
  53. 53.
    Cianflone K, Maslowska M, Sniderman AD (1995) The acylation stimulating protein-adipsin system. Int J Obesity 19:S34–S38Google Scholar
  54. 54.
    Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703PubMedCrossRefGoogle Scholar
  55. 55.
    Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRefGoogle Scholar
  56. 56.
    Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMedGoogle Scholar
  57. 57.
    Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRefGoogle Scholar
  58. 58.
    Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMedCrossRefGoogle Scholar
  59. 59.
    Frübeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA (2001) The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280:E827–E847Google Scholar
  60. 60.
    Raymond NC, Dysken M, Bettin K et al (2000) Cytokine production in patients with anorexia nervosa, bulimia nervosa, and obesity. Int J Eating Disord 28:293–302CrossRefGoogle Scholar
  61. 61.
    Bastard JP, Jardel C, Bruckert E et al (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338–3342PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Josep M. Argilés
    • 1
  • Vanessa Almendro
    • 1
  • Sílvia Busquets
    • 1
  • Francisco J. López-Soriano
    • 1
  1. 1.Cancer Research Group, Department of Biochemistry and Molecular BiologyUniversity of BarcelonaBarcelonaSpain

Personalised recommendations